News coverage about Zymeworks (NYSE:ZYME) has been trending positive on Thursday, according to Accern Sentiment Analysis. The research group identifies negative and positive media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Zymeworks earned a coverage optimism score of 0.26 on Accern’s scale. Accern also assigned media stories about the company an impact score of 45.870095664698 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

Several equities research analysts have weighed in on the stock. Cormark reissued a “buy” rating on shares of Zymeworks in a research report on Saturday, September 30th. Barclays reissued an “underweight” rating and set a $8.00 price target on shares of Zymeworks in a research report on Thursday, September 7th. Zacks Investment Research raised shares of Zymeworks from a “sell” rating to a “hold” rating in a research report on Saturday, September 9th. Finally, Scotiabank cut shares of Zymeworks from an “overweight” rating to an “underweight” rating in a research report on Thursday, September 7th. Two investment analysts have rated the stock with a sell rating and five have issued a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $14.35.

Shares of Zymeworks (NYSE:ZYME) traded down $0.12 during midday trading on Thursday, reaching $8.24. 7,800 shares of the company’s stock traded hands, compared to its average volume of 22,833. Zymeworks has a 1-year low of $6.25 and a 1-year high of $14.25.

TRADEMARK VIOLATION WARNING: This story was published by Watch List News and is owned by of Watch List News. If you are reading this story on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The correct version of this story can be accessed at

Zymeworks Company Profile

Zymeworks Inc is a Canada-based clinical-stage biopharmaceutical company. The Company focuses on the discovery, development and commercialization of multifunctional biotherapeutics. The Company’s ZymeCAD platform is for protein modeling and structure-guided protein engineering. The Company’s platforms include Azymetric Platform, AlbuCORE Platform, EFECT Platform and Zymelink Conjugation Platform + Cytotoxins.

Receive News & Ratings for Zymeworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zymeworks and related companies with's FREE daily email newsletter.